Grow Opportunity

Cannabis producer WeedMD to use BLOCKstrain’s proprietary platform.

WeedMD will be the first Licensed Producer under Health Canada's Access to Cannabis for Medical Purposes Regulations to use BLOCKStrain's proprietary platform, making it an early adopter of blockchain technology in the cannabis industry.

BLOCKStrain said it's platform will allow WeedMD's library of cannabis genetics to expand.

May 30, 2018  By Grow Opportunity Staff

BLOCKStrain said it's platform will allow WeedMD's library of cannabis genetics to expand.

BLOCKStrain, which began trading publicly last week on the TSX Venture Exchange, delivers a secure blockchain platform to establish global certainty for cannabis strains and their ownership.

BLOCKstrain CEO Robert Galarza said his company will work with WeedMD to better shape their core product suite, and to provide digital solutions that reduce inefficiencies and administrative pain points.

“Our mission is to provide WeedMD with a secure record for their vast array of genetics, while also assisting in streamlining certain internal functions given our technology platform and knowledge,” he said.

BLOCKStrain’s team has worked hand in hand with the team at WeedMD to create a digital process for automating the “Production Batch Record” summary which is part of the documentation requirements set by the federal government.


Currently the mandated process, although necessary for consumer safety and quality assurance, is burdensome, time intensive and requires far too much manual paperwork.

BLOCKStrain said they use mobile devices and tablets to removes many redundancies currently in the current system.

BLOCKStrain has also developed a “Wholesale Record” summary to assist in the WeedMD’s wholesale genetics business, giving WeedMD the ability to manage and share the history of a clone, as well as the data collected during its grow cycle.

The digital archival system of BLOCKStrain is also expected to prevent forms from being damaged, lost or tampered with and to make it easy to share with colleagues and regulatory bodies.

Print this page


Stories continue below